AU2007297310B2 - Improved immunoassay methods - Google Patents

Improved immunoassay methods Download PDF

Info

Publication number
AU2007297310B2
AU2007297310B2 AU2007297310A AU2007297310A AU2007297310B2 AU 2007297310 B2 AU2007297310 B2 AU 2007297310B2 AU 2007297310 A AU2007297310 A AU 2007297310A AU 2007297310 A AU2007297310 A AU 2007297310A AU 2007297310 B2 AU2007297310 B2 AU 2007297310B2
Authority
AU
Australia
Prior art keywords
antigen
test sample
antibody
cancer
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007297310A
Other languages
English (en)
Other versions
AU2007297310A1 (en
Inventor
Tony Barnes
Caroline Chapman
Andrea Murray
John Forsyth Russell Robertson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncimmune Ltd
Original Assignee
Oncimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0618055A external-priority patent/GB2441824A/en
Application filed by Oncimmune Ltd filed Critical Oncimmune Ltd
Publication of AU2007297310A1 publication Critical patent/AU2007297310A1/en
Application granted granted Critical
Publication of AU2007297310B2 publication Critical patent/AU2007297310B2/en
Assigned to ONCIMMUNE LIMITED reassignment ONCIMMUNE LIMITED Amend patent request/document other than specification (104) Assignors: ONCIMMUNE LTD
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
AU2007297310A 2006-09-13 2007-09-12 Improved immunoassay methods Ceased AU2007297310B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84415806P 2006-09-13 2006-09-13
GB0618055.8 2006-09-13
GB0618055A GB2441824A (en) 2006-09-13 2006-09-13 Immunoassay method
US60/844,158 2006-09-13
PCT/GB2007/003486 WO2008032084A1 (en) 2006-09-13 2007-09-12 Improved immunoassay methods

Publications (2)

Publication Number Publication Date
AU2007297310A1 AU2007297310A1 (en) 2008-03-20
AU2007297310B2 true AU2007297310B2 (en) 2013-11-07

Family

ID=38626957

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007297310A Ceased AU2007297310B2 (en) 2006-09-13 2007-09-12 Improved immunoassay methods

Country Status (8)

Country Link
EP (1) EP2062053B1 (ja)
JP (3) JP5495159B2 (ja)
AU (1) AU2007297310B2 (ja)
CA (1) CA2663154C (ja)
HK (1) HK1131210A1 (ja)
IL (1) IL197487A (ja)
PL (1) PL2062053T3 (ja)
WO (1) WO2008032084A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
GB2424070B (en) 2002-11-14 2007-06-27 Univ Nottingham Methods for preparing tumour marker proteins
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
RU2636532C2 (ru) 2005-05-27 2017-11-23 Онкиммьюн Лимитед Улучшенные способы иммуноанализа
US8574848B2 (en) 2006-09-13 2013-11-05 Oncimmune Ltd. Immunoassay methods
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
EP2446272A2 (en) 2009-06-23 2012-05-02 Eventus Diagnostics Israel Ltd. A method and system for the detection of cancer
JP5257788B2 (ja) * 2009-12-02 2013-08-07 日東紡績株式会社 クラスリン重鎖とその自己抗体との複合体の免疫測定方法、それに用いるキット及びそれを用いた癌判定方法
WO2012027631A2 (en) * 2010-08-26 2012-03-01 University Of Washington Through Its Center For Commercialization Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells
DE102010047069A1 (de) * 2010-10-01 2012-04-05 Universitätsklinikum Kiel Schleswig-Holstein Differenzialdiagnostik von Pankreasadenomen
JP6074677B2 (ja) * 2012-08-07 2017-02-08 学校法人北里研究所 膀胱癌診断用ポリペプチドマーカー及び膀胱癌診断用キット並びにこれらを使用する方法
JP6371063B2 (ja) * 2013-01-30 2018-08-08 国立大学法人 岡山大学 悪性腫瘍の検査方法および抗腫瘍剤
JP6588893B2 (ja) * 2013-09-18 2019-10-09 アデレード リサーチ アンド イノベイション ピーティーワイ エルティーディーＡｄｅｌａｉｄｅ Ｒｅｓｅａｒｃｈ ＆ Ｉｎｎｏｖａｔｉｏｎ Ｐｔｙ Ｌｔｄ 卵巣がんの自己抗体バイオマーカー
WO2015117951A1 (en) * 2014-02-04 2015-08-13 Celltrend Gmbh Diagnosis of cancer by detecting auto-antibodies against egf-receptor
GB201403489D0 (en) * 2014-02-27 2014-04-16 Univ London Queen Mary Biomarkers for endometriosis
KR20160135749A (ko) * 2014-03-18 2016-11-28 샌포드 헬스 유방암 검출용 시약 및 검출 방법
ES2876038T3 (es) 2018-02-18 2021-11-11 Marquez Marquez Lidia Método, aparato y kit para la detección temprana de cáncer de mama
WO2020097901A1 (en) * 2018-11-16 2020-05-22 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy
WO2020034061A1 (en) * 2018-08-13 2020-02-20 Beijing Percans Oncology Co., Ltd. Biomarkers for cancer therapy
WO2024057956A1 (ja) * 2022-09-12 2024-03-21 チューニングフォーク・バイオ・インク ｐ５３アイソフォーム変異体のがん診断用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058978A2 (en) * 1998-05-11 1999-11-18 The University Of Nottingham Tumour markers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60196669A (ja) * 1984-03-21 1985-10-05 Hitachi Ltd 抗原抗体反応用分析方法および装置
JP3005400B2 (ja) * 1993-09-16 2000-01-31 株式会社トクヤマ 抗原または抗体濃度の測定方法
JP3476274B2 (ja) * 1995-04-24 2003-12-10 積水化学工業株式会社 免疫測定法
JPH10239317A (ja) * 1996-12-28 1998-09-11 Shinotesuto:Kk 地帯現象抑制測定方法及び測定試薬
JP2004500569A (ja) * 2000-02-25 2004-01-08 ルミネックス　コーポレイション 多重アッセイ法のための内部標準および内部対照
GB2424070B (en) * 2002-11-14 2007-06-27 Univ Nottingham Methods for preparing tumour marker proteins
JP2005049264A (ja) * 2003-07-30 2005-02-24 Fujikura Kasei Co Ltd 標的物質の測定方法および測定試薬
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058978A2 (en) * 1998-05-11 1999-11-18 The University Of Nottingham Tumour markers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Kumar, S. et al., Vet Res., 2003, vol. 34, no. 1, pages 71-83 *
Pare, J. et al., J. Vet. Diagn. Invest., 1995, vol. 7, pages 352-359 *

Also Published As

Publication number Publication date
PL2062053T3 (pl) 2013-05-31
JP5736598B2 (ja) 2015-06-17
WO2008032084A1 (en) 2008-03-20
EP2062053A1 (en) 2009-05-27
JP5495159B2 (ja) 2014-05-21
CA2663154A1 (en) 2008-03-20
HK1131210A1 (en) 2010-01-15
AU2007297310A1 (en) 2008-03-20
IL197487A0 (en) 2009-12-24
EP2062053B1 (en) 2012-12-05
CA2663154C (en) 2016-02-23
JP2014016364A (ja) 2014-01-30
JP2012255797A (ja) 2012-12-27
IL197487A (en) 2013-08-29
JP2010503845A (ja) 2010-02-04

Similar Documents

Publication Publication Date Title
AU2007297310B2 (en) Improved immunoassay methods
US8927223B2 (en) Immunoassay methods
AU2006250923B2 (en) Improved immunoassay methods
US9714938B2 (en) Immunoassay methods
EP2444812B1 (en) Improved immunoassay methods
AU2012209004B2 (en) Improved immunoassay methods

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired